elearning

Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning
Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.
Management of Chronic Lymphocytic Leukaemia in Older Patients
Modulo
English
0 CME Points

Público destinatarios

This module is for medical practitioners who wish to learn about the SIOG guidelines for the management of chronic lymphocytic leukaemia in elderly patients.

Objetivos educativos

By the end of this module, you should be able to understand:

  • The role of co-morbidity assessment, geriatric assessment and frailty screening in elderly patients with CLL.
  • The importance of prognostic factors in elderly patients with CLL.
  • The relevant predictive factors in elderly patients with CLL.
  • The initial treatment of elderly patients with CLL.
  • The treatment of elderly patients with recurrent CLL.

Requisitos del sistema

This module requires the learner to have a good, stable internet connection and runs best on INTERNET EXPLORER 7 AND ABOVE, and MOZILLA FIREFOX on either Windows or MacOS. FLASH ADD ON is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact info@ecancer.org and we will get back to you as soon as possible.

Política de divulgación

ecancer and Dr Alessandra Ferrajoli, Professor of Medicine Leukaemia, University of Texas M.D. Anderson Cancer Center, Texas, USA have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this SIOG e-learning module which was made possible through an unrestricted educational grant from Janssen Pharmaceutical.

Soporte

Production of this module was funded by the International Society of Geriatric Oncology (SIOG) and by an unrestricted grant from Janssen.